FOQUEST has now been included on the Newfoundland and Labrador Prescription Drug Program (NLPDP) as of Aug 30, 2023
FOQUEST is now listed on the Newfoundland and Labrador Prescription Drug Program (NLPDP) benefit list as an Open Benefit for the treatment of persons with Attention Deficit Hyperactivity Disorder, effective Aug 30, 2023.
Learn more about the eligibility criteria for reimbursement of FOQUEST in Newfoundland and Labrador.
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.